Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Vorinostat in Recurrent/Metastatic HNSCC and Salivary Gland Cancer
NCT02538510Phase 2Completed
- Sponsor
- University of Washington
- Start
- Oct 2015
- Primary completion
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, vorinostat in head and neck squamous cell carcinoma (HNSCC), salivary gland carcinoma (SGC), sponsored by University of Washington. Started Oct 2015; status: completed.
02
Drugs
pembrolizumabvorinostat
03
Conditions
head and neck squamous cell carcinoma (HNSCC)salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT02538510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538510.